SCHEMBL255964

SCHEMBL255964

O=S1(=O)Cc2ccccc2C1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.64
MEN1 O00255 1/20 0.64
CYP1A2 P05177 1/20 0.41
TSHR P16473 1/20 0.38
MAOA P21397 3/20 0.36
CES1 P23141 2/20 0.36
CYP2A6 P11509 1/20 0.35
MAOB P27338 2/20 0.33
HTR2C P28335 1/20 0.33
DRD2 P14416 1/20 0.33
DRD1 P21728 1/20 0.33
DRD4 P21917 1/20 0.33
DRD5 P21918 1/20 0.33
DRD3 P35462 1/20 0.33
BCHE P06276 1/20 0.33
GPR3 P46089 1/20 0.33
DHODH Q02127 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29657671 1.00 KMT2A (0.64) KMT2AMEN1CYP1A2TSHRMAOA
SCHEMBL255961 0.82 MEN1 (0.46) KMT2AMEN1CYP1A2TSHRMAOA
SCHEMBL8279267 0.78 KMT2A (0.48) KMT2AMEN1CYP1A2MAOACES1
SCHEMBL31534672 0.78 KMT2A (0.48) KMT2AMEN1CYP1A2MAOACES1
SCHEMBL25757622 0.77 MEN1 (0.41) KMT2AMEN1CYP1A2TSHRMAOA
SCHEMBL11841056 0.76 MEN1 (0.58) KMT2AMEN1CYP1A2TSHRCES1
SCHEMBL31424341 0.73 MEN1 (0.43) KMT2AMEN1CES1DRD2DRD3
SCHEMBL11454483 0.73 MEN1 (0.43) KMT2AMEN1
SCHEMBL4872275 0.73 MEN1 (0.43) KMT2AMEN1CYP1A2
SCHEMBL24089931 0.71 KMT2A (0.42) KMT2AMEN1CYP1A2TSHRCES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 804 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3286166-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2020-05-13 EP claimed
US-10221129-B2 Inhibitors of human immunodeficiency virus replication VIIV Healthcare UK (No.5) Limited (GB) 2019-03-05 US claimed
US-20180086697-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-29 US claimed
EP-3286166-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2018-02-28 EP claimed
WO-2016172424-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2016-10-27 WO claimed
US-7511065-B2 Mixed lineage kinase modulators ELI LILLY AND COMPANY (US) 2009-03-31 US claimed
US-20080113977-A1 Mixed Lineage Kinase Modulators ELI LILLY AND COMPANY 2008-05-15 US claimed
US-6103912-A OPTICAL INFRARED FILTERS COMPRISING PH SENSITIVE DYES POLAROID CORPORATION (US) 2000-08-15 US claimed
US-4219648-A 7-[[Amino(1,3-dihydrobenzo[c]thienyl)acetyl]amino]cephalosporin derivatives RICHARDSON-MERRELL INC. (US) 1980-08-26 US claimed
EP-4540230-A1 ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF Ensem Therapeutics, Inc. (US) 2025-04-23 EP disclosed
WO-2024126453-A1 NEW SUBSTITUTED INDOLE-2-CARBOXAMIDES AS PHGDH INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-06-20 WO disclosed
WO-2024088991-A1 HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-05-02 WO disclosed
WO-2024089006-A1 HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-05-02 WO disclosed
WO-2024089155-A1 HETEROCYCLIC COMPOUNDS AS STING ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-05-02 WO disclosed
US-5136049-A Reacting a heterocyclic-containing ketone, aldehyde, acyl halide or ester and 3-sulfolane, 1,3-dihydrobenzothiophene, naphtho(2,3-c)furan or thiophene or phenanthra(9,10-c)furan or thiophene WACKER-CHEMIE GMBH (DE) 1992-08-04 US disclosed
WO-1991004027-A1 NEW N-ARYL AND N-HETEROARYLAMIDE AND UREA DERIVATIVES AS INHIBITORS OF ACYL COENZYME A: CHOLESTEROL ACYL TRANSFERASE (ACAT) PFIZER INC. (US) 1991-04-04 WO disclosed
EP-0418071-A2 New N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase PFIZER INC. (US) 1991-03-20 EP disclosed
EP-0409413-A2 Diaryl ether heterocycles IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-01-23 EP disclosed
US-4231920-A METAL SALTS OF SULFONIC ACID AND A COSOLVENT GENERAL ELECTRIC COMPANY (US) 1980-11-04 US disclosed
US-4219648-A 7-[[Amino(1,3-dihydrobenzo[c]thienyl)acetyl]amino]cephalosporin derivatives RICHARDSON-MERRELL INC. (US) 1980-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10221129-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR2E, POLR2H KMT2A 3450/4885MEN1 4300/4885CYP1A2 2403/4885
US-20180086697-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2E, POLR2H KMT2A 3450/4885MEN1 4300/4885CYP1A2 2403/4885
US-20080113977-A1 Mixed Lineage Kinase Modulators MYLK2, CSNK1G2, CSNK1A1 KMT2A 1757/4885MEN1 4347/4885CYP1A2 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.